30 completed, 18 recruiting, 17 active not recruiting, 9 terminated. 87 Phase 1, 32 Phase 2.
Follow osimertinib: new trials by email Literature Review of osimertinib trials Research Report on osimertinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer Lurbinectedin, Osimertinib - Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Misty Shields | 16 | 2027-01-01 | 2026-10-15 |
| A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer ANS014004 + PLB1004, ANS014004 + Osimertinib - Non-Small Cell Lung Cancer, EGFR Mutation | Phase 1 / Phase 2 | Not yet recruiting | Beijing Pearl Biotechnology Limited Liability Company | 253 | 2026-06-01 | 2025-12-16 |
| Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors IBI3005, Sintilimab, Bevacizumab biosimilar - Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 282 | 2026-06-01 | 2026-05-28 |
| Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib Capivasertib in combination with Osimertinib - Lung Cancer (NSCLC), Lung Cancer (Non-Small Cell) | Phase 1 / Phase 2 | Not yet recruiting | Shanxi Province Cancer Hospital | 53 | 2026-05-15 | 2026-03-24 |
| A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer Ivonescimab, Dato-DXd, Osimertinib - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 66 | 2026-04-09 | 2026-07-13 |
| Zorifertinib With Osimertinib for NSCLC With Meningeal Progression Zorifertinib and Osimertinib Combination Therapy - Patients With Advanced Non-small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment | Phase 1 | Recruiting | Alpha Biopharma (Jiangsu) Co., Ltd. | 42 | 2026-01-31 | 2026-06-22 |
| Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer NXP900, Osimertinib - EGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients | Phase 1 | Recruiting | Nuvectis Pharma, Inc. | 18 | 2025-12-18 | 2026-07-09 |
| A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC Osimertinib (Tagrisso®), WSD0922-FU - Non Small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Recruiting | Wayshine Biopharm, Inc. | 48 | 2025-10-17 | 2025-11-28 |
| Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8) DZD6008, Sunvozertinib, Osimertinib - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Dizal Pharmaceuticals | 220 | 2025-07-30 | 2026-10-23 |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors BMS-986507, Osimertinib, Pembrolizumab - Lung Cancer, Breast Cancer | Phase 1 / Phase 2 | Recruiting | Bristol-Myers Squibb | 416 | 2025-02-04 | 2026-09-23 |
| A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes Test Product HYP-6589, Osimertinib - Solid Tumor | Phase 1 / Phase 2 | Recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 115 | 2024-11-27 | 2026-10-21 |
| A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies KQB198, Osimertinib, Amivantamab - Solid Tumor, Adult | Phase 1 | Active not recruiting | Kumquat Biosciences Inc. | 92 | 2024-06-03 | 2026-09-02 |
| A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations BPI-1178, Osimertinib - NSCLC | Phase 1 | Unknown | National Cancer Center, China | 20 | 2024-05-22 | 2024-07-10 |
| A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC GH21, Tagrisso - Non-Small Cell Lung Cancer With EGFR Mutation | Phase 1 / Phase 2 | Recruiting | Suzhou Genhouse Bio Co., Ltd. | 94 | 2024-03-05 | 2024-07-08 |
| Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients Nintedanib, gefitinib, erlotinib, afatinib, osimertinib - Non-small Cell Lung Cancer, EGFR Gene Mutation | Phase 1 / Phase 2 | Recruiting | China Medical University Hospital | 20 | 2024-02-23 | 2025-01-23 |
| Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer GDC-1971, Osimertinib, Cetuximab - Colorectal Cancer, Non-Small Cell Lung Cancer | Phase 1 | Completed | Genentech, Inc. | 10 | 2024-01-08 | 2025-11-13 |
| Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer Cetuximab, Osimertinib, Tucatinib - Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Not yet recruiting | Jonathan Riess | 36 | 2024-01-01 | 2023-10-05 |
| The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC LMV-12(HE003) - Non Small Cell Lung Cancer, RET Gene Mutation | Phase 1 / Phase 2 | Recruiting | Hunan Province Tumor Hospital | 120 | 2023-12-31 | 2024-05-30 |
| Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer Osimertinib, Carotuximab - Non Small Cell Lung Cancer, Lung Cancer | Phase 1 | Recruiting | Karen Reckamp, MD, MS | 60 | 2023-09-15 | 2026-08-06 |
| A Study of DB-1310 in Advanced/Metastatic Solid Tumors DB-1310, Trastuzumab, Osimertinib - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | DualityBio Inc. | 1000 | 2023-08-17 | 2026-04-06 |
Showing 20 of 87. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (54) · Lung Neoplasms (25) · Neoplasms (12) · Neoplasm Metastasis (6) · Colorectal Neoplasms (4) · Thoracic Neoplasms (4) · Brain Neoplasms (3) · Bronchial Neoplasms (3) · Carcinoma (3) · Lung Diseases (3) · Neoplasms by Site (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Adenocarcinoma (2) · Breast Neoplasms (2)
AstraZeneca (13) · Memorial Sloan Kettering Cancer Center (4) · National Cancer Institute (NCI) (4) · M.D. Anderson Cancer Center (3) · AbbVie (2) · Blueprint Medicines Corporation (2) · Daiichi Sankyo (2) · Allist Pharmaceuticals, Inc. (1) · Alpha Biopharma (Jiangsu) Co., Ltd. (1) · Ascentage Pharma Group Inc. (1) · Beijing Pearl Biotechnology Limited Liability Company (1) · BioNTech SE (1) · Bristol-Myers Squibb (1) · Case Comprehensive Cancer Center (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1)
United States (57) · China (21) · South Korea (18) · Taiwan (16) · Spain (14) · France (12) · Australia (9) · United Kingdom (9) · Japan (8) · Italy (6) · Canada (5) · Netherlands (5) · Belgium (3) · Germany (3) · Poland (2)
Helena Yu, MD (4) · Jonathan W Riess (2) · Serban Ghiorghiu, MSD (2) · Anjali Rohatgi, M.D., Ph.D. (1) · Barbara O'Brien, MD (1) · Caicun Zhou, Doctorate (1) · Caroline Germa, MD (1) · Charu Aggarwal, MD, MPH (1)
PMID 25923549, PMID 27435396, PMID 29151359, PMID 30512189, PMID 11099318, PMID 11937001, PMID 11948464, PMID 15258838, PMID 15844174, PMID 15897941, PMID 16805854, PMID 16983123, PMID 16990388, PMID 17150016, PMID 18172267, PMID 18245491, PMID 18612161, PMID 19624979, PMID 20156778, PMID 20595147, PMID 20627894, PMID 20818862, PMID 21215350, PMID 21488898, PMID 21499124, PMID 21670455, PMID 21784628, PMID 21844012, PMID 22271810, PMID 23552882, PMID 23937717, PMID 2406000, PMID 24714359, PMID 25175099, PMID 25299645, PMID 25305457, PMID 25336382, PMID 25695221, PMID 25747273, PMID 26181354, PMID 26334749, PMID 26473643, PMID 26494259, PMID 27354477, PMID 27751847, PMID 27843613, PMID 27959700, PMID 28260924, PMID 28408243, PMID 28577957
2014 (3), 2017 (2), 2015 (1), 2016 (1), 2023 (1), P30CA033572 (1), P30CA093373 (1), P30CA138292 (1), P50CA217691 (1), UM1CA186644 (1), UM1CA186689 (1), UM1CA186709 (1), UM1CA186712 (1), UM1CA186717 (1)